** Shares of Glenmark Pharmaceuticals GLEN.NS fall as much as 2.5% to 2,229 rupees; set for the third session of losses

** A coalition of 48 states and territories in the United States reached a $29.6 million settlement with GLEN and will make installment payments through 2030

** They accuse the co of helping inflate prices of generic drugs and limiting competition

** GLEN denied wrongdoing but agreed to cooperate with ongoing state lawsuits and make changes to ensure compliance with antitrust law

** Ten analysts have a "Buy" rating on average; median PT is 2,575 rupees - data compiled by LSEG

** YTD, GLEN up 10.5%